摘要:
Compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).
摘要:
This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.
摘要:
This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.
摘要:
The invention aims at providing highly effective insecticides. Compounds represented by the general formula (1); insecticides containing the same as the active ingredient; and a process for the production thereof: (1) wherein A1, A2, A3 and A4 are each carbon, nitrogen, or oxidized nitrogen; R1 and R2 are each hydrogen, optionally substituted alkyl, or the like; G1 and G2 are each oxygen or sulfur; X's may be the same or different from each other and are each hydrogen, halogeno, C1-3 alkyl, or trifluoromethyl; n is an integer of 0 to 4; Q1 is optionally substituted phenyl, an optionally substituted heterocyclic group, or the like; and Q2 is a phenyl or heterocyclic group having one or more substituents, at least one of the substituents being C1-4 haloalkoxy or the like.
摘要:
Compounds of Formula I and Formula II, and their N-oxides and agriculturally suitable salts, are disclosed that are useful for controlling invertebrate pests, Formula (I), Formula (II) wherein A, B, J, R1, R2, R3, R4, and n are as defined in the disclosure.Also disclosed are compositions comprising the compounds of Formula I or Formula II and methods for controlling invertebrate pests that involve contacting the invertebrate pests or their environment with an effective amount of a compound of Formula (I) or Formula (II).
摘要:
Die Erfindung betrifft substituierte 1- und 2-Naphthol-Mannichbasen, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen sowie die Verwendung dieser Verbindungen zur Herstellung von Arzneimitteln.
摘要:
Compounds or their salts having general formulas (I) and (II): wherein s is and integer equal to 1 or 2, preferably s = 2; A is the radical of a drug and is such as to meet the pharmacological tests reported in the description, C and C1 are two bivalent radicals. The precursors of the radicals B and B1 are such as to meet the pharmacological test reported in the description.
摘要:
Compounds of formula (Ia), (Ib) or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R (m) represents up to 6 substituents, K represents -O-, -S-, -CH2-, -N(R )- or -N(COR )-, in which R is H or C1 to C3 alkyl, W is a carbonyl, sulphonyl or sulphinyl group, and X is a carbonyl, sulphonyl or sulphinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors.
摘要:
Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
摘要:
A method of treating an ocular disorder in a subject associated with aberrant all- trans -retinal clearance in the retina, the method comprising administering to the subject a therapeutically effective amount of a primary amine compound of formula: wherein R 1 is an aliphatic and/or aromatic compound; the primary amine compound upon administration to the subject forming a reversible Schiff-base with theall- trans -retinal or its metabolite including A2E and retinal dimer without adversely affecting normal retinoid cycle performance; the primary amine compound when administered to a Rdh8 -1- Abca4 -1- mouse increasing the optical coherence tomography score of the mouse to at least about 2.5 and increasing 11-ds-retinal amount at least about 30% in comparison to untreated control animal, wherein the primary amine compound is not a local anesthetic, which includes an aromatic amine, that demonstrates sodium channel blockade when administered to the subject.